Cem Karaali, Department of General Surgery, University of Health Sciences, Izmir Faculty of Medicine, Izmir City Hospital, Izmir, Turkey
Huseyin Esin, Department of General Surgery, Izmir City Hospital, Izmir, Turkey
Emel E. Pala, Department of Pathology, University of Health Sciences, Izmir Faculty of Medicine, Izmir City Hospital, Izmir, Turkey
Murat Keser, Department of Medical Oncology, University of Health Sciences, Izmir City Hospital, Izmir, Turkey
Olçun U. Unal, Department of Medical Oncology, University of Health Sciences, Izmir City Hospital, Izmir, Turkey
Orhan Ureyen, Department of General Surgery, University of Health Sciences, Izmir Faculty of Medicine, Izmir City Hospital, Izmir, Turkey
Mustafa Emiroglu, Department of General Surgery, University of Health Sciences Izmir Tepecik Training and Research Hospital, Izmir. Turkey
Objective: The main goal in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is to achieve a pathologic complete response (pCR). Our study examines whether neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), NLR/PLR, systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation-value (PIV) indices can be used to determine pCR and prognosis. Methods: The study included 228 patients who received NAC for breast cancer between 2010 and 2021. Results: Fifty-nine (25.9%) patients had pCR to NAC. In univariate analysis, a significant difference was found between clinical node status, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), breast cancer molecular subtypes, and pCR (p < 0.05). However, in multivariate analysis, only breast cancer molecular subtypes and HER2 status were significantly associated with pCR (p < 0.05). Conclusions: Our study did not find a significant relationship between NLR, PLR, MLR, NLR/PLR, SII, SIRI, and PIV indices and pCR, disease-free survival, and overall survival in breast cancer patients who received NAC.
Keywords: Neoadjuvant chemotherapy. Breast cancer. Disease-free survival.